A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
Standard
A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. / Schnittger, S; Bacher, Ulrike; Kern, W; Haferlach, T; Hertenstein, B; Haferlach, C.
In: LEUKEMIA, Vol. 22, No. 4, 4, 2008, p. 856-858.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
AU - Schnittger, S
AU - Bacher, Ulrike
AU - Kern, W
AU - Haferlach, T
AU - Hertenstein, B
AU - Haferlach, C
PY - 2008
Y1 - 2008
M3 - SCORING: Zeitschriftenaufsatz
VL - 22
SP - 856
EP - 858
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 4
M1 - 4
ER -